| Learning Objective #1: Identify Quality of Life markers in the postmenopausal period expressed in a cohort of African American women recruited from the urban mid-south | |||
| Learning Objective #2: Discuss the difference in Quality of Life following short-term administration of estrogen/progestin in these women |
Objective: Three and one half million African American (AA) women are expected to enter menopause over the next 20 years, yet few studies address menopause and long term effects on Quality of Life (QOL) in this group of women. In many studies on Hormone Replacement Therapy (HRT), few participants have been AA. Since publication of data from The Women’s Health Initiative, many questions have been posed regarding effects of estrogen/progestin. In this oral presentation, data will be presented regarding the effect of HRT on QOL in a cohort of AA postmenopausal women.
Design: A secondary analysis will be conducted from data collected within a larger funded study, PACE (Postmenopausal African Americans and Cardiovascular effects of Estrogen/progestin), to be completed January 2003. AA women (N=70) have been randomized to a daily regimen of conjugated equine estrogens(CEE) 0.625mg + medroxyprogesterone acetate(MPA) 2.5 mg or placebo. Primary variables examined are cardiovascular variables in women between the ages of 45-65 years of age living in the urban Mid-South. Data are collected at enrollment and 12 weeks. Secondary variables on QOL are being collected using the Menopause Specific QOL (MENQOL) instrument.
Results: Reported from enrollment data, mean age for participants is 52.5 years with mean age of menopause 45.68 years. Average length of time since last cycle is 5.7 years. Only 22% of women report previous HRT use. Socioeconomic variables suggest group is less than national average in income with 68% reporting total household income of <$20,000, although 67% report being employed. Enrollment QOL scores reflect the greatest perceived dysfunction to be within vasomotor domain (X=4.6/8). Differences between enrollment and 12 week QOL values will be evaluated and presented following the close of the study.
Conclusions: To be presented upon close of study in January 2003.
Back to Posters
Back to 14th International Nursing Research Congress
Sigma Theta Tau International
10-12 July 2003